Webcast

Prior to joining Dell Med, Dr. Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida. He has served as president of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP) and sits on the Scientific Advisory Board and board of directors of the American Foundation for Suicide Prevention (AFSP) and the Anxiety and Depression Association of America (ADAA).

He is a member of the APA Council on Research and chairs both the APA Research Colloquium for Young Investigators and the APA Work Group on Biomarkers and Novel Treatments.

His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1,100 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.

He has also served on the Mental Health Advisory Council of National Institute of Mental Health and the Biomedical Research Council for NASA; is co-editor in chief (with Alan F. Schatzberg, M.D.) of the Textbook of Psychopharmacology, published by the APA Press and now in its fifth edition; co-editor in chief of a new text book on Post-Traumatic Stress Disorders, and is the co-editor in chief of a new journal published by Elsevier: Personalized Medicine in Psychiatry.

He received his M.D. and Ph.D. (Neurobiology) degrees at the University of North Carolina (UNC) School of Medicine. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke and at Emory University before relocating to the University of Miami in 2009.

Ned H. Kalin, MD, is Hedberg Professor and Chairman of the Department of Psychiatry at the University of Wisconsin School of Medicine and Public Health. He is the Director of the HealthEmotions Research Institute and the Lane Neuroimaging Laboratory, a Professor in the Department of Psychology at the University of Wisconsin, and an affiliate scientist at the Wisconsin Regional Primate Center and the Harlow Primate Laboratory. He serves as the principal investigator for several ongoing NIH funded research projects and has published over 250 peer-reviewed articles related to the adaptive and maladaptive expression of emotion and anxiety, and the childhood risk to develop anxiety disorders and depression. His research focuses on uncovering basic mechanisms that relate stress to the development of psychopathology and to understanding the mechanisms that cause some children to be vulnerable for the development of anxiety and depression. In addition to his research activities, he treats patients who suffer from anxiety and depression who are refractory to standard treatment.

Dr. Kalin earned his medical degree from Jefferson Medical School in Philadelphia, Pennsylvania, did his residency in the Department of Psychiatry at the University of Wisconsin, and a fellowship in Neuropsychopharmacology at the National Institute of Mental Health. Dr. Kalin is board certified by the American Board of Psychiatry and Neurology. He is a Fellow Emeritus of the American College of Neuropsychopharmacology and a fellow of the American College of Psychiatry. He has been recognized for numerous awards including the 1985 A.E. Bennett Award for basic science research in biological psychiatry, the 2005 Edward A. Strecker Award, the 2007 American College of Psychiatrists Award for research in mood disorders, the 2007 Gerald Klerman Senior Investigator Award, and the 2015 Anna-Monika Prize of the European College of Neuropsychopharmacology. In 2013 he was inducted as a Fellow in the American Association for the Advancement of Science, and in 2015 he was elected as a member of the National Academy of Medicine. In 2017, Dr. Kalin was inducted as a Distinguished Life Fellow of the American Psychiatric Association. He has served as President of the International Society of Psychoneuroendocrinology and President of the Society of Biological Psychiatry, as a member of the National Advisory Mental Health Council and as Co-Editor for the international journal, Psychoneuroendocrinology. In 2019, Dr. Kalin was appointed as the Editor-in-Chief of the American Journal of Psychiatry.

Dr. Mease received undergraduate and medical degrees from Stanford University and completed residency in internal medicine and fellowship in rheumatology at the University of Washington. He directs the Rheumatology Research Division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. His major research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA). His work includes research on disease state, development of outcome measures, and determining the efficacy and safety of emerging therapies for these conditions. Dr. Mease has authored over 490 journal articles, numerous abstracts, and book chapters. He is past president, founding organizer, and current treasurer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and a member of its Collaborative Research Network (CRN) steering committee. He is also a member of the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). Dr. Mease is active in the Outcome Measures in Rheumatology Clinical Trials (OMERACT) organization as co-chair of the PsA and chronic pain working groups and as a steering committee member. He is the Scientific Director of the PsA and SpA arms of the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Dr. Mease is co-chair of the PsA task force of the National Psoriasis Foundation, which in 2019 awarded him a lifetime achievement award for his work in advancing the field of PsA.

Allan Gibofsky, MD, JD, MACR, FACP, FCLM, serves as Professor of Medicine in the Department of Healthcare Policy and Research at Weill Cornell Medicine. Dr Gibofsky is an attending physician and rheumatologist at the Hospital for Special Surgery, where he is Co- Director of the Clinic for Inflammatory Arthritis. He received his undergraduate degree from Brooklyn College of the City University of New York, his medical degree from Weill Medical College of Cornell University, and his law degree from Fordham University School of Law. He did his internship in pathology, followed by a residency in medicine at New York Hospital. He completed a fellowship in rheumatology/immunology jointly at Hospital for Special Surgery and at The Rockefeller University. Dr Gibofsky has authored or co-authored numerous papers and textbook chapters, primarily on rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular, for his basic and clinical studies on rheumatic fever.

Currently Secretary-Treasurer of The New York Rheumatism Association, Dr Gibofsky is past Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and is a recipient of its Physicians’ Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees and was Chair for Professional Education. Dr Gibofsky has participated in numerous professional and public education programs, nationally and internationally. He served as President of The American College of Rheumatology and was recently named a Master. Dr Gibofsky is a Jonas Salk Scholar of the City University and an Alumnus of the Year of Brooklyn College. He is past President of the American College of Legal Medicine and is past Chair of the American Board of Legal Medicine. Dr Gibofsky is past Chair of the Arthritis Advisory Committee of the Food and Drug Administration and continues as a special consultant to that committee.

Michael K. Racke received his M.D. from the University of Medicine and Dentistry of New Jersey-New Jersey Medical School. He completed his neurology training at Emory University in Atlanta and a neuroimmunology fellowship at the National Institutes of Health. His first faculty position was at Washington University in St. Louis, where he was the recipient of a Harry Weaver Neuroscience Junior Faculty Award from the National Multiple Sclerosis Society and the Young Investigator in Multiple Sclerosis of the American Academy of Neurology Education and Research Foundation. He then moved to the University of Texas Southwestern Medical Center where he was Vice Chairman for Neurology Research and also professor in the Center for Immunology. He was chairman of neurology at The Ohio State University School of Medicine from 2006-2014. His research focused on understanding how inflammation is established in the central nervous system and developing novel therapeutics by studying the animal model experimental autoimmune encephalomyelitis. He was instrumental in performing preclinical studies which helped lead to the development of dimethyl fumarate as a treatment for multiple sclerosis. He also participated in research efforts developing anti-CD20 monoclonal antibodies for multiple sclerosis, including the first publication using rituximab in progressive multiple sclerosis. His research also centers on the pathogenesis of multiple sclerosis. Dr. Racke has served on scientific advisory committees for the National Multiple Sclerosis Society, National Institutes of Health, and the Hertie Foundation. He serves on several editorial boards, including JAMA Neurology and the Annals of Neurology, and is the Editor-in-Chief of the Journal of Neuroimmunology. He has served as chairman of the Research Programs Advisory Committee for the National Multiple Sclerosis Society, on the Board of Directors for the American Committee on Treatment and Research in Multiple Sclerosis (ACTRIMS), and as President of the Consortium of Multiple Sclerosis Centers (CMSC), of which he now serves on the Board of Governors. He has been recognized as one of the Best Doctors in America for over 20 years. He is currently the medical director for neurology at Quest Diagnostics.

Dr. Anne H. Cross is a professor of Neurology at Washington University in St. Louis, where she holds the Manny & Rosalyn Rosenthal and Dr. John L. Trotter MS Center Chair in Neuroimmunology and has served as Section Head of the Neuroimmunology/MS Section since 2001.

Raised in Mobile, Alabama, Dr. Cross graduated cum laude from the University of Alabama School of Medicine and was selected for the Alpha Omega Alpha medical honorary. After residency training in adult neurology at George Washington University, she spent several years as a post-doctoral fellow training in neuroimmunology and neuropathology at the National Institute of Health with Drs. Dale McFarlin and Henry McFarland and later at Albert Einstein College of Medicine with Drs. Cedric Raine and Celia Brosnan. Dr.Cross pursued further training in the clinical care of MS patients at Albert Einstein College of Medicine with Dr. Labe Scheinberg and received the Harry Weaver Neuroscience Scholar award of the National Multiple Sclerosis Society in 1990 and the John Jay Dystel Prize in 2019.

Dr. Cross joined the Washington University Department of Neurology in 1991. Her research has been continually funded by the National MS Society, the NIH and/or the U.S. Department of Defense since she opened her laboratory in 1991. Her laboratory currently focuses on advanced imaging studies of progressive MS and the role(s) of B cells and B cell products in MS and its animal models. During her nearly 30 years at Washington University, she has trained more than 30 students, residents, and fellows; she is very proud that they all continue to actively contribute to the research and care of MS and related diseases.

Mitzi Joi Williams is a Board-Certified Neurologist and Fellowship trained Multiple Sclerosis Specialist who serves as the Founder & CEO of the Joi Life Wellness Group Multiple Sclerosis Center in Newnan, GA. She is considered a subject matter expert in Neurology, Multiple Sclerosis, and Health Disparities. Dr. Williams has over 15 years of experience in the field of Multiple Sclerosis. She received her undergraduate degree in Neuroscience and Behavioral Biology from Emory University in Atlanta, GA, and received her Doctor of Medicine Degree from Morehouse School of Medicine, also in Atlanta, Georgia. She completed her Internal Medicine Internship, Neurology Residency, and Multiple Sclerosis Fellowship at Georgia Health Sciences University (formerly MCG) in Augusta, GA, where she received numerous accolades and served as Chief Resident of the Neurology Residency Program.

Dr. Williams has spearheaded and participated in multiple steering committees and work groups to further research in underserved populations with MS, with a focus on the African American population. She has recently joined efforts to increase diversity in clinical trials and educate the community about the importance of research participation. Through collaborations with national and international committees, she advocates for people living with MS to share in the decision-making process with their healthcare teams to combat this disease. Dr. Williams is the author of MS Made Simple: The Essential Guide to Understanding Your Multiple Sclerosis Diagnosis. She continues to live out her mission to provide personalized Multiple Sclerosis Care delivered with expertise, compassion, and joy.

Dr. Rieder is Vice Chair, Co-Director of the IBD Section, Director of IBD Research, and Director of the Advanced IBD Fellowship Program at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is on patients with IBD, with a special emphasis on the pathogenesis, prediction, and therapy of intestinal fibrosis.

He has published more than 130 articles and book chapters and has been recognized for his expertise as indicated through invitations to clinical guideline steering committees of the European Crohn’s and Colitis Organization (ECCO). Dr. Rieder is lead author of the ECCO guidelines on ulcerative colitis and lead author of the first ECCO clinical consensus on diagnosis and management of intestinal fibrosis. He received multiple international invitations as a speaker, session chair, or conference faculty. He serves as an abstract reviewer for all major GI conferences, is past associate editor of Clinical and Translational Gastroenterology, and is on several editorial boards of medical journals.

Dr. Rieder is proud of his significant ties to ECCO, for which he served as the chair of Y-ECCO, member of the ECCO operational board, prior Y-ECCO committee member, and member of the scientific committee. He is past chair of REACH-IBD and Co-Chair of the Professional Education Committee of the Crohn’s & Colitis Foundation. Dr. Rieder is the leading PI on the international Stenosis Therapy and Research (STAR) Consortium with the goal of building a pathway to test anti-fibrotic medications in stricturing Crohn’s disease and was recently awarded the Sherman Emerging Leaders award.

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) is the Joseph B. Kirsner Professor of Medicine, a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology and Nutrition, and Director of the Inflammatory Bowel Disease (IBD) Center at the University of Chicago Medicine in Chicago, Illinois. Dr. Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine in Chicago, Illinois and completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago in Chicago, Illinois, where he served as Chief Resident and Chief Fellow. He also serves as Associate Faculty at the MacLean Center for Clinical Medical Ethics, Associate Investigator at the University of Chicago Comprehensive Cancer Center, and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation, where he also serves as a Board of Trustees member. Dr. Rubin is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease. Prior to these appointments, he served as the Director of the Fellowship in Gastroenterology, Hepatology and Nutrition at the University of Chicago for 11 years. In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn’s & Colitis Foundation’s Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He has previously served as an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis.

Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD, now in its 3^rd edition, was an associate editor of the 11th edition and is senior editor of the upcoming 12^th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. His H index is 74. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular and verified twitter feed @IBDMD with over 20,000 followers.

Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.

Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.

Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co- Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.

Dr. Mease received undergraduate and medical degrees from Stanford University and completed residency in internal medicine and fellowship in rheumatology at the University of Washington. He directs the Rheumatology Research Division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. His major research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA). His work includes research on disease state, development of outcome measures, and determining the efficacy and safety of emerging therapies for these conditions. Dr. Mease has authored over 490 journal articles, numerous abstracts, and book chapters. He is past president, founding organizer, and current treasurer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and a member of its Collaborative Research Network (CRN) steering committee. He is also a member of the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). Dr. Mease is active in the Outcome Measures in Rheumatology Clinical Trials (OMERACT) organization as co-chair of the PsA and chronic pain working groups and as a steering committee member. He is the Scientific Director of the PsA and SpA arms of the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Dr. Mease is co-chair of the PsA task force of the National Psoriasis Foundation, which in 2019 awarded him a lifetime achievement award for his work in advancing the field of PsA.

Atul A. Deodhar, MD, is Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University, Portland. He is board certified in internal medicine and rheumatology and is a fellow of the American College of Rheumatology (ACR) and American College of Physicians.

Dr. Deodhar is a past chair of SPARTAN (Spondyloarthritis Research and Treatment Network), an organization of North American rheumatologists dedicated to education and research in the field of axial spondyloarthritis. He serves on the steering committee of GRAPPA (Group for the Research and Assessment of Psoriasis and Psoriatic Arthritis). He served on the ACR treatment guidelines sub-committee and as the associate editor of the Advanced Rheumatology Course by Association of Health Professionals in Rheumatology (ARHP). Dr. Deodhar has served the ACR in various other capacities as a vice chair of the annual meeting planning committee, member of the peripheral MRI task force, Association of Rheumatology Health Professionals (ARHP) nominating committee, and developer of the ARHP online advanced rheumatology course. He serves on the Rheumatology Board of the American Board of Internal Medicine (ABIM).

Dr. Deodhar is the Deputy Editor of Best Practice and Research Clinical Rheumatology and a guest editor for Current Opinion in Rheumatology. He is a reviewer for Nature Reviews in Rheumatology, Arthritis & Rheumatology, Annals of the Rheumatic Diseases, and Annals of Internal Medicine, among several other journals. His research interests are axial spondyloarthritis and psoriatic arthritis. He has authored three books, over 200 peer-reviewed articles, several book chapters, and editorials. Dr. Deodhar has been a principal or co-investigator in more than 100 clinical trials mostly focused on therapies for ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis.

He completed his fellowship in rheumatology at Oregon Health & Science University and, before that, a research fellowship in rheumatology at the Royal Cornwall Hospital, Truro, England. Dr. Deodhar completed his residency in internal medicine and geriatrics at the Royal Cornwall Hospital, Truro, as well as in the Sassoon General Hospital and King Edward Memorial Hospital, Pune, India. He received his MBBS and MD degrees from the University of Pune, India and his MRCP from the Royal College of Physicians, London, England.

Christopher Ritchlin, MD, MPH, is a Professor of Medicine and Chief of Allergy, Immunology & Rheumatology at the University of Rochester Medical Center in Rochester, New York. He attended medical school at Albany Medical College and completed his medical residency and chief residency at Mount Sinai Hospital in New York. He trained as a fellow in rheumatology at the New York University Medical Center and remained as a postdoctoral fellow for 2 years, and then spent an additional year in the lab of Dr. Robin Poole in Montreal, Canada. Dr. Ritchlin joined the faculty of the University of Rochester School of Medicine and Dentistry in 1991 and in 2009 he earned an MPH degree at the University.

Dr. Ritchlin is engaged in translational research that is centered on mechanisms of bone resorption in psoriatic arthritis and on the role of the lymphatic system in joint flares observed in both rheumatoid and psoriatic arthritis. His laboratory has a number of ongoing projects including circulating osteoclast precursors in inflammatory joint disease and psoriasis, mechanisms of inflammatory osteolysis in psoriatic arthritis, and gene activation profiles in the blood and end organs of patients with immune-mediated inflammatory disorders. The lab is also examining the contribution of circulating dendritic cells to inflammation in rheumatoid and psoriatic arthritis. His research is funded by the NIH, National Psoriasis foundation, Amgen, Centocor, and UCB. Dr. Ritchlin is also a co-investigator in the IPART and CORRONA registries and leads an effort to identify arthritis biomarkers in psoriasis patients. He is a member of the ACR Division Directors Special Committee and is leading efforts to provide basic science online teaching modules to fellows in rheumatology. Dr. Ritchlin also directs the mentoring of junior investigators in the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). He has published over 160 manuscripts on topics related to psoriatic arthritis, lymphatic mechanisms of joint flare, and bone remodeling.